Research programme: thrombopoietin agonists - NascaCell Technologies
Alternative Names: SE-ET-TPO20d; Thrombo plusLatest Information Update: 18 May 2011
At a glance
- Originator NascaCell Technologies
- Class Proteins
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 18 May 2011 Discontinued - Preclinical for Thrombocytopenia in Germany (Parenteral)
- 21 Aug 2006 Preclinical trials in Thrombocytopenia in Germany (Parenteral)